Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Coherus Biosciences Inc (NASDAQ: CHRS) was $0.78 for the day, down -2.87% from the previous closing price of $0.80. In other words, the price has decreased by -$2.87 from its previous closing price. On the day, 0.75 million shares were traded.
Ratios:
Our analysis of CHRS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.10 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 180.62. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -14.10%, while the 200-Day Moving Average is calculated to be -29.63%.
Shares Statistics:
A total of 115.91M shares are outstanding, with a floating share count of 111.33M. Insiders hold about 3.97% of the company’s shares, while institutions hold 51.08% stake in the company.
